HPGC Renmintongtai Pharmaceutical Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 10,349.28 million compared to CNY 9,597.99 million a year ago. Revenue was CNY 10,389.98 million compared to CNY 9,641.09 million a year ago.

Net income was CNY 292.16 million compared to CNY 264.48 million a year ago. Basic earnings per share from continuing operations was CNY 0.5038 compared to CNY 0.4561 a year ago. Diluted earnings per share from continuing operations was CNY 0.5038 compared to CNY 0.4561 a year ago.